

DFW
Box 880



PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)	
)	
Jamieson, J. et al.)	Examiner: Unassigned
)	
Serial No.: 10/582,288)	Art Unit: Unassigned
)	
Filed: June 12, 2006)	Docket No.: R131 1010.1
)	(56308.0002.3)
For: Methods and Compounds for Modulating)	
Triglyceride and VLDL Secretion)	

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

Sir:

Applicants hereby voluntarily disclose the references listed on the attached Form PTO/SB/08A and /08B, pages 1-5, with all documents included on the enclosed CD for the convenience of the Examiner, to the Assistant Commissioner for Patents.


Applicants further reserve the right to establish the patentability of the claimed invention over any of the listed information should they be applied as references, and/or to prove that some of the cited information may not be prior art, and/or to prove that some of the cited information may not be enabling for the teachings they purport to offer. This statement further should not be construed as the representation that an exhaustive search has been made, or that the information cited herewith is material, or that there does not exist information more material to the examination of the present Application. The Examiner is specifically requested not to rely solely on the information submitted herein. On the contrary, the Examiner is requested to conduct an independent and thorough review of the information, and to form independent opinions as to their significance.

It is respectfully requested that the Examiner initial and return copies of the enclosed PTO-1449 and to indicate in the official file wrapper of the above-identified patent application that each item of the cited information has been considered.

If a fee is due, the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **09-0528**. This Information Disclosure Statement is submitted in duplicate.

Respectfully submitted,

Date: 12/12/06



David S. Bradin
Attorney for Applicant
Reg. No. 37,783

Womble Carlyle Sandridge & Rice, PLLC
P.O. Box 7037
Atlanta, GA 30357-0037
(919) 484-2382 (Telephone)
(919) 484-2084 (Facsimile)
Customer No. 26158



E072.1070.1 (50718.0008.5)
Serial No.: 10/566,866

CERTIFICATE OF MAIL

Date of Deposit: December 12, 2006

Type of Documents: Information Disclosure Statement = 2 pages
Certificate of Mail, this page = 1 pages
SB/08A and B = 5 pages
1 Disk
Return Postcard

Total Number of Pages submitted **8 pages**


Title: Methods and Compounds for Modulating
Triglyceride and VLDL Secretion

Serial No. 10/582,288

Filing Date: June 12, 2006

I hereby certify that the above documents are being mailed in an envelope by First Class
mail to:

**Commissioner for Patents
Mail Stop: IDS
P. O. Box 1450
Alexandria, VA 22313-1450**

 (signature)
Donnie S. Dietrich



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	
	Filing Date	June 12, 2006
	First Named Inventor	Jamieson
	Art Unit	
	Examiner Name	
Sheet 1 of 1	Attorney Docket Number	

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		WO 03/066086	08-14-2003	KARSTEN		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ for Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	
		Filing Date	June 12, 2006
		First Named Inventor	Jamieson
		Art Unit	
		Examiner Name	
Sheet 1	of 4	Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Alexander et al., 1976, "Subcellular localization of B apoprotein of plasma lipoproteins in rat liver." J. Cell Biol. 69: 241-263	
		Antonny et al., 1997, "Activation of ADP-ribosylation factor 1 GTPase-activating protein by phosphatidylcholine-derived diacylglycerols." J. Biol Chem, 272, 30848-30351	
		Asp et al., 2000, "ADP-ribosylation factor 1 and its activation of phospholipase D are important for the assembly of very low density lipoproteins." J. Biol Chem, 275, 26285-26292	
		Balsinde, 2002, "Roles of various phospholipases A2 in providing lysophospholipid acceptors for fatty acid phospholipid incorporation and remodelling." Biochem J. 364: 695-702	
		Biederbick et al., 1995, "Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles." Eur. J. Cell Bio. 66: 3-14	
		Blanchette-Mackie et al., 1995, "Perilipin is located on the surface layer of intracellular lipid droplets in adipocytes." J. Lipid Res., 36: 1211-1226	
		Burnett et al., 2003, "A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia." J. Biol. Chem. 278, 13442-13452	
		Chernomordik, L., M. M. Kozlov, and J. Zimmerberg. 1995. "Lipids in biological membrane fusion." J. Membr. Biol. 146:1-14	
		Cui et al, 1995, "Expression of phosphatidylethanolamine N-methyltransferase-2 in McArdle-RH7777 hepatoma cells inhibits the CDP-choline pathway for phosphatidylcholine biosynthesis via decreased gene expression of CTP:phosphocholine cytidyltransferase." Biochem J., 312, 939-945	
		Daleke 2003, "Regulation of transbilayer plasma membrane phospholipid asymmetry." J. Lipd Res, 44, 233-242	
		Dashti et al., 2002, "The N-terminal 1000 residues of apolipoprotein B associate with microsomal triglyceride transfer protein to create a lipid transfer pocket required for lipoprotein assembly." Biochemistry. 41, 6978-6987	
		DeLong et al., 1999, "Molecular distinction of phosphatidylcholine synthesis between the CDP-choline pathway and phosphatidylethanolamine methylation pathway". J. Biol. Chem. 274: 29683-29688.	
		Fisher et al., 2001, "The triple threat to nascent apolipoprotein B. Evidence for multiple, distinct degradative pathways." J. Biol. Chem. 276, 27855-27863	
		Fisher et al., 1998, "Apolipoprotein B metabolism in hypertriglyceridemic diabetic patients administered either a fish oil- or vegetable oil-enriched	

		diet." J. Lipid Res. 39: 388-401	
		Fisher and Ginsberg, 2002, "Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins", J. Biol. Chem. 277,17377-17380	
		Gusarova et al., 2003, "Apolipoprotein B100 exit from the endoplasmic reticulum (ER) is COPII-dependent, and its lipidation to very low density lipoprotein occurs post-ER. ", J. Biol. Chem. 278:48051-48058	
		Harris, 1999, "n-3 fatty acids and human lipoprotein metabolism: an update." Lipids Suppl 34, S257-S258	
		Hebbachi and Gibbons, 2001, "Microsomal membrane-associated apoB is the direct precursor of secreted VLDL in primary cultures of rat hepatocytes. " J. Lipid Res.42, 1609-1617;	
		Hsu et al., 2000, "Effect of n-3 fatty acids on the composition and binding properties of lipoproteins in hypertriglyceridemic patients." Am.J. Clin. Nutr. 71: 28-35	
		Ichimura et al., 2000, "A ubiquitin-like system mediates protein lipidation." Nature 408, 488-492	
		Kabeya et al., 2000, "LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.", EMBO J. 19 (21): 5720-5728	
		Klionsky and Emr, 2000, "Cell biology - Autophagy as a regulated pathway of cellular degradation." Science 290,1717-1721	
		Kotkat et al., 1999, "Effect of dietary fish oil (active EPA-30) on liver phospholipids in young and aged rats." Comp Biochem. Physiol A Mol. Integr. Physiol 122, 283-289	
		Lang and Davis, 1990, "Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes." J. Lipid Res, 31, 2079-2086;	
		McLeod et al. 1996, "Apolipoprotein B sequence requirements for hepatic very low density lipoprotein assembly. Evidence that hydrophobic sequences within apolipoprotein B48 mediate lipid recruitment." J. Biol Chem 271, 18445-18455	
		McLeod et al.,1994, "Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins. " J. Biol. Chem. 269,2852-2862	
		Morrisett et al. "Effects of Sirolimus on Plasma Lipids, Lipoproteins, and Fatty Acid Metabolism in Renal Transplant Patients." J Lipid Res 43:1170-1180, 2002	
		Mizushima et al., 2003, "Role of the Apg12 conjugation system in mammalian autophagy." Int. J. Biochem. and Cell Biology 35,553-561	
		Mizushima et al.,2001, "Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells." J. CellBiol., 152(4): 657-668	
		Murphy and Vance, 1999, "Mechanisms of lipid-body formation.", Trends Biochem. Sci. 24: 109- 115	
		Nestel et al., 1984, "Suppression by diets rich in fish oil of very low density lipoprotein production in man." J. Clin. Invest. 74: 82-89;	
		Nishimaki-Mogami et al, 2002, "Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes." J. Lipid Res. 43, 1035-1045	
		Noga et al, 2002, "An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins." J. Biol Chem, 277, 42358-42365	
		Packard and Shepherd, 1997, "Lipoprotein heterogeneity and apolipoprotein B metabolism", Arterioscler. Thromb.Vasc.Biol. 17, 3542-3556	

		Parks et al., 1989, "Fish oil decreases hepatic cholesteryl ester secretion but not apoB secretion in African green monkeys. " J. Lipid Res. 30: 1535-1544	
		Parks et al., 1990, "Effect of fish oil diet on hepatic lipid metabolism in nonhuman primates: lowering of secretion of hepatic triglyceride but not apoB. " J. Lipid Res. 31: 455-466	
		Phung et al., 1997, "Phosphoinositide 3-kinase activity is necessary for insulin-dependent inhibition of apolipoprotein B secretion by rat hepatocytes and localizes to the endoplasmic reticulum." J. Biol. Chem. 272,30693-30702	
		Reggiori and Klionsky 2002, "Autophagy in the eukaryotic cell." Eukaryot. Cell 1(1) : 11-21	
		Rustaeus et al.,1999, "Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation. "J. Nutr. 129, 463S- 466S;	
		Rustaeus et al., 1998, "The microsomal triglyceride transfer protein catalyzes the post-translational assembly of apolipoprotein B-100 very low density lipoprotein in McA-RH7777 cells." J.Biol, Chem 273, 5196-5203	
		Shelness and Sellers, 2001, "Very-low-density lipoprotein assembly and secretion." Curr. Opin. Lipidol, 12(2): 151-157	
		Stillemark et al., 2000, "The assembly and secretion of apolipoprotein B-48-containing very low density lipoproteins in McA-RH7777 cells." J. Biol. Chem. 275,10506-10513	
		Stromhaug et al., 1998, "Purification and characterization of autophagosomes from rat hepatocytes." Biochem. J. 335,217-224	
		Sullivan et al., 1986, "Paradoxical elevation of ldl apoprotein - b levels in hypertriglyceridemic patients and normal subjects ingesting fish oil atherosclerosis", Atherosclerosis, 61: 129-134	
		Tran et al., 1998, "Functional analysis of disulfide linkages clustered within the amino terminus of human apolipoprotein B.", J. Biol. Chem 273,7244-7251	
		Tran et al., 2000, "The assembly of very low density lipoproteins in rat hepatoma McA-RH7777 cells is inhibited by phospholipase A2 antagonists.", J. Biol Chem 275, 25023-25030	
		Tran et al.,2002, "Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH7777 cells.", J. Biol. Chem. 277, 31187-31200	
		Ueno et al.,1991, "Membrane markers of endoplasmic reticulum preserved in autophagic vacuolar membranes isolated from leupeptin-administered rat liver. " J. Biol. Chem, 266,18995-18999	
		Verkade et al., 1993, "Impaired biosynthesis of phosphatidylcholine causes a decrease in the number of very low density lipoprotein particles in the Golgi but not in the endoplasmic reticulum of rat liver." J. Biol. Chem. 268(33): 24990-24996	
		Vukmirica et al.,2002, "The N-linked oligosaccharides at the amino terminus of human apoB are important for the assembly and secretion of VLDL." J. Lipid Res. 43,1496-1507	
		Wang et al., 1995, "Degradation of apolipoprotein B in cultured rat hepatocytes occurs in a post-endoplasmic reticulum compartment." J. Biol. Chem. 270,24924-24931	
		Wang et al, 1999, "The activity of microsomal triglyceride transfer protein is essential for accumulation of triglyceride within microsomes in McA-RH7777 cells. A unified model for the assembly of very low density lipoproteins." J. Biol Chem 274, 27793-27800	
		Wong and Nestel, 1987, "Eicosapentaenoic acid inhibits the secretion of triacylglycerol and of apoprotein B and the binding of LDL in Hep G2 cells."	

		Atherosclerosis 64,139-146	
		Yao et al., 1997, "Intracellular degradation of newly synthesized apolipoprotein B." J. Lipid Res. 38, 1937-1953	
		Yao and Vance, 1988, "The active synthesis of phosphatidylcholine is required for very low density lipoprotein secretion from rat hepatocytes." J. Biol Chem. 263, 2998-3004	
		Yamamoto et al., 1990, "Characterization of the isolation membranes and the limiting membranes of autophagosomes in rat hepatocytes by lectin cytochemistry." J. Histochem. Cytochem. 38,573-580	
		Zhang et al., 2002, "Creating new. fluorescent probes for cell biology." Nat. Rev. Mol. Cell Biol. 3,906-918	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.